masthead-publications

Categories

Filter by Topics

ABC-DLBCL ADCC Gene Alteration Airway Remodeling AKT Targeted Therapy ALK Alleles Angiogenesis Anti-TNF Alpha Therapy Anus Apoptosis AR-Specific T Cells Asthma Autocrine Signaling Autoimmune Disorder AXL B-cell lines B-cell lymphoma Biofluid Biology of neoplasia Biomarker Biomarker Analysis Biomarker Discovery Biomarker Patient Stratification Biomarker Validation Biomarkers Biomarkers Outcome Bladder Bladder Cancer blood Brain Brain RNA Breast Breast Cancer Cancer Immune Response Carcinoma Cardio Vascular Disease cardiovascular disease CD-19 CD44 CDKN2A mutation Cell line Cells Cerebral Spinal Fluid Checkpoint Inhibitors Chemoresistance Chronic Obstructive Pulmonary Disease Circulating miRNAs Circulating Tumor Cells Classification Clinical Outcome Prediction Clinical Trials cMET Coccidioidomycosis Colon Colon cancer Colorectal cancer Comparative Approach Comparative Study Comparison study Comprehensive Gene Expression Study Cord Blood Buffy Coat Core Needle Biopsy Custom mRNA Cyclin E mRNA Cytokines Detection Developmental Immunotherapy Diabetes Diagnostic Biomarkers Differential Diagnosis Differential Expression Differential Gene Expression Analysis Diffuse large B-cell lymphoma Dissecting Genomic Biomarkers DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT EMT-mediated resistance Encephalophy Epidemiology outcomes Epigenetics Epigenomic Epstein-Barr ERBB2 Esophageal Cancer Exosomes Extracellular Vesicles Extracted RNA Fabry Disease Feasibility FFPE FFPE Canine Tumor FGF Ligand Trap FGFR Fibrous Tumors Gastrointestinal Cancers Gene Expression Analysis Gene Expression Comparisons Gene Expression Profiling Gene Expression Signatures Gene Fusions Gene Pathway Analysis Genetic Polymorphism Genomic Genomic Bioinformatics Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel Human Human serum Hypoxia Immune Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Tolerance Immune-checkpoint blockade Immune-related Colitis Immuno-Oncology Immunofluorescence Immunology Immunotherapy Induction Chemotherapy Inflammation Inflammatory Signatures Interferon Gamma Signature Invasive Breast Carcinoma Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver Lung Lung Adenocarcinoma Lung cancer Lung Carcinoma Lupus Lymph Node Metastasis Lymphoma Mechanism of Action Melanoma Mesothelioma MET Metastatic Colon Cancer Metastatic Prostate Cancer Methods Comparison Mice Mice PDX Microenvironment miRNA miRNA WTA miRQC study Molecular Characterization Mouse Mouse mRNA mRNA mRNA custom mRNA expression in tumors mTOR pathway mTORC1 mTORC2 Mucin Hypersecretion Multiple Myeloma Muscle Mutations MYC Myocardial Reperfusion Myocarditis NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Nivolumab non-Hodgkin Lymphoma Non-small Cell Lung Cancer Novel Therapeutic Targets NSCLC NTRK1 Oesophageal Adenocarcinoma Oncogenes Oncology Oncomirs Oral Cancer Oral Squamous Cell Carcinoma Osteoclast Ovarian cancer Overexpression P13KmTOR Inhibitor Palbociclib Pancreas Pancreatic Cancer Pancreatic Ductal Adenocarcinoma Pancreatic ductal adenocarcinoma Paralysis Parkinson's Disease Pathogenesis Pathology Pathway Analysis Pathways PCA Cell Lines PD-1 Pd-L1 PD-L1 Phase 3 clinical trial PI3K signaling pathway PIK3CA mutation plasma Plasma Platform Comparison Pralatrexate predictive Predictive Biomarkers Predictive Modeling Pro-inflammatory cytokines Profiling Profiling Signature Development Prognostic Prognostic Biomarkers Programmed cell death protein 1 Programmed death ligand 1 Progression free-survival Prostate Prostate Cancer qNPA qPCR Radiation Toxicities Radioimmunotherapy Rearrangements rectum Regulation Renal Cell Carcinoma Renal Disease Responders vs Non-responders Response rate RET Reveal Rheumatoid Arthritis Risk Score Rituximab ROS1 safety Sarcoidosis Sarcoma SCBC SCLC Serum Signaling Inhibitors Signaling Pathways Signature Development Signature Pathway Analysis Signature Validation Signatures Sinonasal Undifferentiated Carcinoma Skin Small bowel Small cell bladder cancer Small Cell Bladder Cancer Small Cell Lung Cancer SPECS Lung Consortium Squamous cell carcinoma Sub-typing Surveillance Survival Outcomes Survival plots Synovial Fluid System Validation Systemic Lupus Erythematousus T cell T-cells Technology Comparison Therapeutic Response Therapeutic targets Tissue-based biomarkers TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Triple Negative Breast Cancer Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Mutational Burden tumor mutational burden Type 1 diabetes Urothelial carcinoma Uveal melanoma VEGFR Venetoclas Vistusertib WNT Path Signaling Xenograft Tissue

2020

Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era

Hwang, M., et al. Sarcomatoid Renal Cell Carcinoma Demonstrates an Immunosuppressive Tumor Microenvironment - Implication for Therapeutic Benefit in the Immunotherapy Era.  Poster session presented at: United Sstates and Canadian Academy of Pathology (USCAP) 109th Annual Meeting 2020 FEB 29- MAR 5, Los Angeles, CA

Download pptx 4.4MB

Next Generation Sequencing and Functional Pathway Analysis to Understand the Mechanism of Action of Copper-Tolfenamic Acid Against Pancreatic Cancer.

Hurtado, M., et al. Next Generation Sequencing and Functional Pathway Analysis to Understand the Mechanism of Action of Copper-Tolfenamic Acid Against Pancreatic Cancer. Process Biochemistry 2020: 89: 155-164

View External Link

Circulating microRNAs as Potential Biomarkers for Monitoring the Response to In Vivo Treatment With Rituximab in Systemic Lupus Erythematosus Patients

Cecchi, I., et al. Circulating microRNAs as Potential Biomarkers for Monitoring the Response to In Vivo Treatment With Rituximab in Systemic Lupus Erythematosus Patients. Autoimmunity Reviews 2020; 9(202) article 102488 In Press

Download pdf 929KB

Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial.

Naseem, M., et al. Variation in Genetic Polymorphisms and Gene Expression of HLA-E to Predict Outcomes in Metastatic Colorectal Cancer (mCRC) Patients (pts) Treated with First-line FOLFIRI/Cetuximab: Data from the Phase III FIRE-3 Trial. Poster session presented at Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 245)

View External Link

CCR5 Δ32 mutation and gene expression to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC phase III trials.

Lenz, A., et al. CCR5 Δ32 mutation and gene expression to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and MAVERICC phase III trials.  Poster session presented at 2020 Gastrointestinal Cancers Symposium. 2020 Jan 25. San Francisco, CA. J Clin Oncol 38, 2020 (suppl 4; abstr 170)

View External Link

Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.

Battaglin, F., et al. Genetic variants in R-Spondin/RNF43 complex and gene expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial. Poster session  Clin Oncol 38, 2020 (suppl 4; abstr 190) presented at 2020 Gastrointestinal Cancers Symposium; 2020 Jan 25; San Francisco, CA.

View External Link

Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Woment with Treatment-Naïve Metastatic Breast Cancer

Finn, R. S., et al. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Woment with Treatment-Naïve Metastatic Breast Cancer. Clinical Cancer Research | Precision Medicine and Imaging. 2020 Jan 15. 26:110-21. DOI: 10.1158/1078-0432.CCR-19-0751.

Download pdf 1.4MB

Page last updated March 10, 2020